瑞银发表研报指，石药集团(01093.HK) 去年业绩逊预期，主要受到第四季盈利受压，以及研发及销售费用比率提升的影响，展望2025年管理层预期增长将持平。基于最新业绩表现及公司指引，瑞银将石药的目标价从7.2元下调至7元，今明两年纯利预测分别下调9.2%及5.5%，维持“买入”评级。(gc/u)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-01 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.